Skip to main content
SpringerLink
Log in

Rationale for Focal Therapy

  • Chapter
  • First Online:
Technical Aspects of Focal Therapy in Localized Prostate Cancer

  • 654 Accesses

Abstract

Incidence rates for prostate cancer have been increasing for the last three decades and this is mainly due to earlier diagnoses of asymptomatic diseases by the use of the prostate-specific antigen (PSA) test and PSA screening. In the pre-PSA era, during the decade before 1976, prostate cancer incidence was increasing slowly (2 % per year), when half of all prostate cancers were incidentally detected in transurethral resection chips for benign prostatic hyperplasia treatment or diagnosed by clinical symptoms and digital rectal examination in more advanced diseases. Early detection efforts were associated with a rapid increase in prostate cancer incidence after 1986, from 2 to 12 % per year, with a peak in 1992 (237.2 per 100,000 men in the USA). In the subsequent 3 years, from 1992 to 1995, a 10 % per year decline occurred. During the following decade (1995–2005), prostate cancer incidence stabilized, but to a higher level (150.5 per 100,000) than those in 1986 (119 per 100,000). USA prostate cancer incidence was estimated at 238,590 in 2013.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Meigs JB, Barry MJ, Giovannucci E, et al. High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia. Am J Med. 1998;104:517–25.

    Article  CAS  PubMed  Google Scholar 

  2. Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr. 2012;45:152–6.

    Article  Google Scholar 

  3. Quaglia A, Lillini R, Crocetti E, Buzzoni C, Vercelli M, AIRTUM Working Group. Incidence and mortality trends for four major cancers in the elderly and middle-aged adults: an international comparison. Surg Oncol. 2013;22(2):e31–8.

    Article  PubMed  Google Scholar 

  4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    Article  PubMed  Google Scholar 

  5. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81.

    Article  CAS  PubMed  Google Scholar 

  6. Jemal A, Siegal R, Xu J, XU J. CA statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  7. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR, CaPSURE. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003;170(6 Pt 2):S21–5; discussion S26–7. Erratum in: J Urol. 2004 Feb;171(2 Pt 1):811.

    Article  PubMed  Google Scholar 

  8. Budäus L, Spethmann J, Isbarn H, Schmitges J, Beesch L, Haese A, Salomon G, Schlomm T, Fisch M, Heinzer H, Huland H, Graefen M, Steuber T. Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. BJU Int. 2011;108(8):1256–61.

    Article  PubMed  Google Scholar 

  9. Gallina A, Chun FKH, Suardi N, Eastham JA, Perrotte P, Graefen M, Hutterer G, Huland H, Klein EA, Reuther A, Montorsi F, Briganti A, Shariat SF, Roehrborn CG, delaTaille A, Salomon L, Karakiewicz PI. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int. 2008;101:1513–8.

    Article  PubMed  Google Scholar 

  10. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868–78.

    Article  PubMed  Google Scholar 

  11. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst. 2009;101(19):1325–9.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981–90.

    Article  PubMed  Google Scholar 

  13. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725–32.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19:175–81.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Kvåle R, Auvinen A, Adami HO, Klint A, Hernes E, Møller B, Pukkala E, Storm HH, Tryggvadottir L, Tretli S, Wahlqvist R, Weiderpass E, Bray F. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007;99(24):1881–7.

    Article  PubMed  Google Scholar 

  16. Quaglia A, Parodi S, Grosclaude P, Martinez-Garcia C, Coebergh JW, Vercelli M. Differences in the epidemic rise and decrease of prostate cancer among geographical areas in Southern Europe: an analysis of differential trends in incidence and mortality in France, Italy and Spain. Eur J Cancer. 2003;39:654–65.

    Article  CAS  PubMed  Google Scholar 

  17. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8.

    Article  PubMed  Google Scholar 

  18. Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD, PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9. Erratum in: N Engl J Med. 2009 Apr 23;360(17):1797.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Lin K, Lipsitz R, Miller T, Janakiraman S, U.S. Preventive Services Task Force. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:192–9.

    Article  PubMed  Google Scholar 

  20. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–34.

    Article  PubMed  Google Scholar 

  21. Klotz L. Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes. 2013;20(3):204–9.

    Article  CAS  PubMed  Google Scholar 

  22. Crawford ED, Grubb 3rd R, Black A, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol. 2011;29:355–61.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368(5):436–45.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–61.

    Article  CAS  PubMed  Google Scholar 

  25. Johansson E, Steineck G, Holmberg L, et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 2011;12:891–9.

    Article  PubMed  Google Scholar 

  26. Glass AS, Cooperberg MR, Carroll PR. Early detection of prostate cancer: more information, more clarity. Eur Urol. 2012;62(5):753–5; discussion 755–6.

    Article  PubMed  Google Scholar 

  27. Schröder FH, Hugosson J, Carlsson S, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2012;62:745–52.

    Article  PubMed  Google Scholar 

  28. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126–31.

    Article  PubMed  Google Scholar 

  29. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203–13.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. NIH State-of-the-Science Conference. Role of active surveillance in the management of men with localized prostate cancer. 2011. Available at: http://consensus.nih.gov/2011/prostate.htm. Accessed 21 Dec 2011.

  31. Lecornet E, Ahmed HU, Hu Y, et al. The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation. J Urol. 2012;188:974–80.

    Article  PubMed  Google Scholar 

  32. Carlsson S, Sandin F, Fall K, Lambe M, Adolfsson J, Stattin P, Bill-Axelson A. Risk of suicide in men with low-risk prostate cancer. Eur J Cancer. 2013;49:1588–99.

    Article  PubMed  Google Scholar 

  33. Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M. The role of active surveillance in the management of prostate cancer. J Natl Compr Canc Netw. 2013;11(2):183–7.

    PubMed  Google Scholar 

  34. Bill-Axelsen A, Holmberg L, Mirrja R, et al. Watchful waiting and prostate cancer. NEJM. 2005;352:1977–84.

    Article  Google Scholar 

  35. Merrill RM, Stephenson RA. Trends in mortality rates in patients with prostate cancer during the era of prostate specific screening. J Urol. 2000;163:503–10.

    Article  CAS  PubMed  Google Scholar 

  36. Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L, International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007;178(6):2260–7.

    Article  PubMed  Google Scholar 

  37. Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 2012;13(6):622–32.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011;59:477–94.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. H.Black Chair in Surgical Oncology, Chief of Urology Department, Jewish General Hospital, McGill University, Pavilion E-941, 3755 Chemin de la Cote Sainte Catherine, Montreal, QC, H3T 1E2, Canada

    Franck Bladou MD

Authors
  1. Franck Bladou MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franck Bladou MD .

Editor information

Editors and Affiliations

  1. Department of Urology, Institut Montsouris, Paris-Descartes University, Paris, France

    Eric Barret

  2. Department of Urology, Hôpital Pasteur 2 – Centre Hospitalier Universitaire de Nice, Antipolis, France

    Matthieu Durand

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag France

About this chapter

Cite this chapter

Bladou, F. (2015). Rationale for Focal Therapy. In: Barret, E., Durand, M. (eds) Technical Aspects of Focal Therapy in Localized Prostate Cancer. Springer, Paris. https://doi.org/10.1007/978-2-8178-0484-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0484-2_1

  • Published:

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0483-5

  • Online ISBN: 978-2-8178-0484-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation